Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Overview
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Companies Involved in Therapeutics Development
Immune System Key Ltd
Onspira Therapeutics Inc
Paradigm Biopharmaceuticals Ltd
Paras Biopharmaceuticals Finland Oy
ProteoThera Inc
Ribomic Inc
Swedish Orphan Biovitrum AB
XL-protein GmbH
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Drug Profiles
akinra - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
akinra biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize IL-1R1 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IP-1510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBIL-1RA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nerofe - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-130 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Dormant Products
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Discontinued Products
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Product Development Milestones
Featured News & Press Releases
Oct 03, 2018: Results from the aGO study - a phase 2 study with akinra in patients with acute gout
Sep 21, 2018: Phase2a Nerofe study has begun in Rabin and Kaplan medical centers
Sep 20, 2018: New way to target advanced breast cancers
Apr 11, 2018: Kineret (akinra) approved in the EU for the treatment of Still’s disease
Mar 26, 2018: Drug reduces inflammation in stroke patients
Feb 23, 2018: Kineret (akinra) receives a positive opinion from CHMP for the treatment of Still’s disease
Nov 21, 2017: Successful Completion of Phase I Nerofe Trial on Solid Tumor
Nov 16, 2017: First patient randomised in a phase 3 study evaluating safety and efficacy of akinra in the treatment of Still’s disease
May 30, 2017: Kineret approved in Cada for the treatment of Neotal-Onset Multisystem Inflammatory Disease
Jan 11, 2017: First patient randomised in a phase II study evaluating safety and efficacy of akinra in the treatment of acute gout
Jun 06, 2016: Pfizer CentreOne to manufacture Sobi’s Kineret drug substance
Apr 21, 2016: European patent granted on new formulation of Kineret (akinra)
Feb 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (akinra)
Nov 01, 2015: Immune System Key: Nerofe’s Triple Action
Aug 19, 2015: Kineret receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Immune System Key Ltd, H2 2019
Pipeline by Onspira Therapeutics Inc, H2 2019
Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2019
Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2019
Pipeline by ProteoThera Inc, H2 2019
Pipeline by Ribomic Inc, H2 2019
Pipeline by Swedish Orphan Biovitrum AB, H2 2019
Pipeline by XL-protein GmbH, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019